ecancermedicalscience

Research

Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting

11 Feb 2021
Anjana Joel, Namrata Mathew, Shalom Sylvester Andugala, Sherin Daniel, Birla Roy Gnanamuthu, Ajoy Oommen John, Josh Thomas Georgy, Raju Titus Chacko, Aparna Irodi, Bijesh Yadav, Subhashini John, Ashish Singh

Purpose: Primary mediastinal germ cell tumours (PMGCTs) are rare; with limited data available about their outcomes and optimal treatment in the low middle income countries setting. We studied the clinical profile of patients with PMGCT treated at our centre in order to estimate their survival outcomes and to identify prognostic factors affecting the same.

Patients and methods: Fifty-seven patients with PMGCTs treated between April 2001 and June 2019 were included. Baseline characteristics, details of first line chemotherapy, response rates, toxicity and surgical outcomes were noted. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method.

Results: Among 57 male patients (seminoma = 20 and nonseminomatous = 37), the median follow-up was 10 months (range: 1–120 months). For mediastinal seminoma, 9 (45%) and 11 (55%) patients had good and intermediate risk disease, respectively. Nineteen patients (95%) received BEP (Bleomycin, etoposide and cisplatin) chemotherapy. 94.7% had partial responses and median event-free survival was not reached. All patients were alive and disease free at 2 years. For primary mediastinal nonseminomatous germ cell tumours (PMNSGCTs), all patients were poor risk. Thirty-four (91.8%) received BEP/EP chemotherapy as first line. Responses were PRM (partial response with elevated markers) in 7 (20.5%) and PRM− in 12 (35.2%). The incidence of febrile neutropenia was 50% and 55.8% in seminole and PMNSGCT, respectively. The median OS was 9.06 months and median PFS was 4.63 months for PMNSGCT. The proportion of patients alive at 1 year and 2 years were 35% and 24.3%, respectively.

Conclusion: Primary mediastinal seminomas are rarer and have better survival outcomes. Treatment of PMNSGCT is still a challenge and is associated with poorer survival outcomes.

Related Articles

Groesbeck Preer Parham, Kabongo Mukuta Mathieu, Tankoy Gombo YouYou, Michael L Hicks, Ronda Henry-Tillman, Alex Mutombo, Mukanya Mpalata Anaclet, Mulumba Kapuku Sylvain, Leeya Pinder, Maya M Hicks, Louis Kanda, Mirielle Kanda
Michael L Hicks, Alex Mutombo, Tankoy Gombo YouYou, Mukanya Mpalata Anaclet, Mulumba Kapuku Sylvain, Kabongo Mukuta Mathieu, Ronda Henry-Tillman, Dorothy Lombe, Maya M Hicks, Leeya Pinder, Louis Kanda, Mirielle Kanda, Groesbeck P Parham
Kabongo Mukuta Mathieu, Tankoy Gombo YouYou, Michael L Hicks, Alex Mutombo, Mukanya Mpalata Anaclet, Mulumba Kapuku Sylvain, Leeya Pinder, Maya M Hicks, Louis Kanda, Mirielle Kanda, Groesbeck P Parham, Ronda Henry-Tillman
Tankoy Gombo YouYou, Kabongo Mukuta Mathieu, Michael L Hicks, Ronda Henry-Tillman, Alex Mutombo, Mukanya Mpalata Anaclet, Mulumba Kapuku Sylvain, Maya M Hicks, Leeya Pinder, Louis Kanda, Mirielle Kanda, Groesbeck P Parham
Ranjeeta Subedi, Atul Budukh, Sandhya Chapagain, Pradip Gyanwali, Bishal Gyawali, Kopila Khadka, Chanda Thakur, Uma Dahal, Rajesh Dikshit, Anjani Kumar Jha, Meghnath Dhimal
Suzanne T Nethan, Dhirendra N Sinha, Ashwini Kedar, Vipin Kumar, Shashi Sharma, Roopa Hariprasad, Ravi Mehrotra